spironolactone has been researched along with ANS (Autonomic Nervous System) Diseases in 2 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the effects of spironolactone on cardiac sympathetic nerve activity (CSNA) and left ventricular (LV) remodelling in patients with ST-segment elevation myocardial infarction (STEMI)." | 9.15 | Effects of spironolactone on cardiac sympathetic nerve activity and left ventricular remodelling after reperfusion therapy in patients with first ST-segment elevation myocardial infarction. ( Ichikawa, S; Kasama, S; Kumakura, H; Kurabayashi, M; Matsumoto, N; Minami, K; Sato, Y; Sumino, H; Takayama, Y; Toyama, T, 2011) |
| "Aldosterone has a variety of detrimental effects on the heart and vasculature and is increasingly recognized as an important target in chronic heart failure, as illustrated by the Randomized Aldactone Evaluation Study." | 6.42 | The role of aldosterone in heart failure and the clinical benefits of aldosterone blockade. ( Davies, JI; Dawson, A; Struthers, AD, 2004) |
| "To evaluate the effects of spironolactone on cardiac sympathetic nerve activity (CSNA) and left ventricular (LV) remodelling in patients with ST-segment elevation myocardial infarction (STEMI)." | 5.15 | Effects of spironolactone on cardiac sympathetic nerve activity and left ventricular remodelling after reperfusion therapy in patients with first ST-segment elevation myocardial infarction. ( Ichikawa, S; Kasama, S; Kumakura, H; Kurabayashi, M; Matsumoto, N; Minami, K; Sato, Y; Sumino, H; Takayama, Y; Toyama, T, 2011) |
| "Aldosterone has a variety of detrimental effects on the heart and vasculature and is increasingly recognized as an important target in chronic heart failure, as illustrated by the Randomized Aldactone Evaluation Study." | 2.42 | The role of aldosterone in heart failure and the clinical benefits of aldosterone blockade. ( Davies, JI; Dawson, A; Struthers, AD, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kasama, S | 1 |
| Toyama, T | 1 |
| Sumino, H | 1 |
| Kumakura, H | 1 |
| Takayama, Y | 1 |
| Minami, K | 1 |
| Ichikawa, S | 1 |
| Matsumoto, N | 1 |
| Sato, Y | 1 |
| Kurabayashi, M | 1 |
| Dawson, A | 1 |
| Davies, JI | 1 |
| Struthers, AD | 1 |
1 review available for spironolactone and ANS (Autonomic Nervous System) Diseases
| Article | Year |
|---|---|
The role of aldosterone in heart failure and the clinical benefits of aldosterone blockade.
Topics: Aldosterone; Autonomic Nervous System Diseases; Endomyocardial Fibrosis; Eplerenone; Heart Failure; | 2004 |
1 trial available for spironolactone and ANS (Autonomic Nervous System) Diseases
| Article | Year |
|---|---|
Effects of spironolactone on cardiac sympathetic nerve activity and left ventricular remodelling after reperfusion therapy in patients with first ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty; Autonomic Nervous System Diseases; Collagen Type III; Double-Blind Method; Female | 2011 |